Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy

Lignende værker

• Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial
  af: Akamatsu, Hiroaki, et al.
  Udgivet: (2018)
• Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients
  af: Inoue, Akira, et al.
  Udgivet: (2016)
• Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3
  af: Kato, Terufumi, et al.
  Udgivet: (2015)
• Echinoderm microtubule‐associated protein‐like 4–anaplastic lymphoma kinase‐targeted therapy for advanced non‐small cell lung cancer: Molecular and clinical aspects
  af: Okamoto, Isamu, et al.
  Udgivet: (2012)
• Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset
  af: Kiura, Katsuyuki, et al.
  Udgivet: (2018)